Program
ABBV-6628
A development code.
In AbbVie's pipeline, C5
. Its studies are mostly in Geographic Atrophy, led by AbbVie.
Furthest: phase 2, since Aug 12, 20251 company-led study, 1 open or runningNext primary completion: Oct 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 11 open or running | phase 2since Aug 12, 2025 | Aug 12, 2025 | Oct 2029phase 2 · NCT07160179 |
- Named in AbbVie’s own pipeline as
ABBV-6628
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2025First study: phase 2 study in Geographic AtrophyFirst studyNCT07160179 · 66 planned · United States
Ahead
- Oct 2029Primary completion: phase 2 study in Geographic AtrophyNCT07160179
TargetBeta
“C5”the company's pipeline, read by Claude · source
Other programs on C5
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eculizumabrule | AstraZeneca | phase 4 | 38 |
| ravulizumabrule | AstraZeneca | phase 4 | 35 |
| pozelimabrule | Regeneron Pharmaceuticals | phase 4 | 14 |
| zilucoplanrule | UCB | phase 3 | 14 |
| vilobelimabrule | inflarx-gmbh | phase 3 | 13 |
| Crovalimabrule | Hoffmann-La Roche | phase 3 | 10 |
| cemdisiranrule | Regeneron Pharmaceuticals | phase 3 | 10 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07160179Geographic Atrophy · United States | 2 | Recruiting | Oct 2029 | 66 |
How it is read
Names in the registry
- “ABBV-6628”, 1 entry
Codes read as this program: ABBV6628.
Conditions, from the studies’ own filings
- Geographic Atrophy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.